{"id":53826,"date":"2021-07-06T10:06:50","date_gmt":"2021-07-06T10:06:50","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=76024"},"modified":"2021-07-06T10:06:50","modified_gmt":"2021-07-06T10:06:50","slug":"seegene-announces-partnership-with-bio-rad-to-develop-diagnostic-testing-products-for-the-u-s-market","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/seegene-announces-partnership-with-bio-rad-to-develop-diagnostic-testing-products-for-the-u-s-market\/","title":{"rendered":"Seegene\u00a0announces\u00a0partnership\u00a0with Bio-Rad to\u00a0develop diagnostic testing products for the\u00a0U.S. Market"},"content":{"rendered":"
SEOUL, South Korea, July 6, 2021 \/PRNewswire\/ — Seegene Inc. (KQ 096530), a\u00a0South Korean leading biotechnology firm\u00a0has signed a partnership agreement\u00a0with American biotechnology company\u00a0Bio-Rad Laboratories, Inc.\u00a0to\u00a0support entering the\u00a0U.S.\u00a0market.<\/p>\n
Seegene announced\u00a0on June\u00a01 that it has signed a partnership with Bio-Rad, laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products. Under the terms of the agreement, Seegene will provide diagnostic tests for use on Bio-Rad’s CFX96\u2122 Dx Real-Time PCR System for the U.S. market, pending clinical development and approval from the U.S. Food & Drug Administration (FDA).<\/p>\n
According to the ‘Report on the U.S.\u00a0In Vitro Diagnostics market Trend’ released by the\u00a0Korea Trade-Investment Promotion Agency (KOTRA) in 2020, North America is\u00a0a very\u00a0important market, accounting for about 37 percent of the global in vitro diagnostic industry. However,\u00a0it has been difficult for newer foreign companies to enter the U.S. market because the market has already been dominated by well-established\u00a0global companies and the U.S. government prioritizes its domestic products.\u00a0Under such circumstances, the supply deal with Bio-Rad, a biotech giant with over 60 years of history, is expected to be a significant step forward for Seegene in entering the U.S. market.<\/p>\n
Founded in 1952, Bio-Rad is a global leader in the fields of life science and clinical diagnostics.\u00a0The company has been\u00a0Seegene’s\u00a0major partner\u00a0over the past ten years. Previously, Seegene\u00a0was able to\u00a0generate some 1 trillion won worth of sales revenue by applying its diagnostic assays to Bio-Rad’s PCR systems that had already been installed globally. This new partnership is expected to streamline the process for Seegene\u00a0to seek U.S.\u00a0FDA clearance and the partnership of the\u00a0two\u00a0world\u00a0class\u00a0companies\u00a0
Seegene plans to submit applications for FDA approval for\u00a0its diagnostic\u00a0reagent\u00a0made of the firm’s\u00a0high-multiplex diagnostic technology,\u00a0which is\u00a0unique in its capability to simultaneously screen\u00a0multiple target genes\u00a0on a high throughput real time PCR system.\u00a0Using\u00a0Seegene’s proprietary technologies, it\u00a0can\u00a0also\u00a0selectively amplify\u00a0target genes\u00a0while identifying\u00a0different viruses and the number of viruses. Thanks to the deal,\u00a0Seegene\u00a0will partner with Bio-Rad to plan to seek U.S. FDA clearance and offer a wide range of its products to U.S. customers.<\/p>\n
Under the\u00a0deal,\u00a0Seegene\u00a0intends to seek U.S.\u00a0FDA clearance for clinical assays on Bio-Rad’s real-time PCR system\u00a0‘CFX96\u00a0 (TM)\u00a0<\/sup>Dx\u00a0Real-Time PCR System’.<\/p>\n This includes an intent to clear Seegene’s\u00a0‘AllplexTM<\/sup>\u00a0SARS-CoV- The\u00a0AllplexTM<\/sup>\u00a0SARS-CoV-2\/FluA\/ Ho Yi, Chief Sales and Marketing Officer of Seegene said,\u00a0“To expand our business in the U.S. market,\u00a0it\u00a0is important to work closely with\u00a0a global\u00a0company\u00a0like Bio-Rad\u00a0that has comprehensive network in the region.\u00a0Together with\u00a0Seegene’s\u00a0advanced\u00a0